Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 19/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 19/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9429798 | 0.88 | CDK2AP1 (0.35) | MMP13SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL9429376 | 0.88 | MBTPS1 (0.36) | MMP13SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL9428532 | 0.87 | MCHR1 (0.40) | MMP13SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL9429984 | 0.87 | SLC6A4 (0.39) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL9429749 | 0.85 | EP300 (0.35) | MMP13SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL9429644 | 0.85 | APP (0.37) | MMP13 | |
| SCHEMBL9429417 | 0.84 | ERCC5 (0.39) | MMP13SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9429795 | 0.83 | SLC6A4 (0.34) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL9428841 | 0.82 | HSD17B1 (0.38) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL9428834 | 0.82 | SLC6A4 (0.39) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5328907-A | Treatment of allograft rejection in mammals and antiinflammatory agents | SYNTEX (U.S.A.) INC. (US) | 1994-07-12 | — | — | US | disclosed |
| US-5108999-A | For treating inflammation, autoimmune disease or allograft rejection in mammals | SYNTEX (U.S.A.) INC. (US) | 1992-04-28 | — | — | US | disclosed |
| EP-0440503-A1 | 4-Isoxazolecarboxamide derivatives | SYNTEX (U.S.A.) INC. (US) | 1991-08-07 | — | — | EP | disclosed |
| US-5001124-A | 4-isoxazolecarboxamide derivatives | SYNTEX (U.S.A.) INC. (US) | 1991-03-19 | — | — | US | disclosed |